
InSitu Biologics
InSitu Biologics: An emerging biotech firm developing a prolonged-release drug delivery platform.
- 13
- Private company
- Oakdale, MN, USUnited States
InSitu Biologics is an emerging biotech company dedicated to developing a multi-phase, prolonged-release drug delivery platform aimed at localized treatment of pain, cancer, and infection. Their innovative solutions focus on providing extended-release treatments, which represent a significant opportunity in the multi-billion dollar healthcare market. The company is currently in the investigational pre-clinical stage, with products not yet available for sale.
InSitu Biologics has made notable strides, including a license agreement with the Mayo Clinic, underscoring its potential impact in the biotech industry. The company's approach to drug delivery aims to revolutionize localized treatment methods, potentially improving patient outcomes and reducing systemic side effects.
Similar Companies

Trilogic Pharma
trilogicpharma.com

Extend Biosciences
extendbio.com

Enable Therapeutics

PharmaIN
pharmain.com
Carigent Therapeutics

Viking Scientific
Talima Therapeutics
talima.com

Concept Matrix Solutions

BioSapien
biosapien.com

Advanced Microbubbles

Toralgen
toralgen.com

Syntis Bio
syntis.bio

Cocoon Biotech
cocoonbiotech.com

Sonoran Biosciences
Anogen Life Sciences
therakine.com
LayerBio
layerbio.com
Control Delivery Systems

Mucommune
mucommune.com

Mechano-Therapeutics

Edulis Therapeutics
edulis.xyz
Quick Facts
Who are InSitu Biologics' competitors?
Companies similar to InSitu Biologics include Trilogic Pharma, Extend Biosciences, Enable Therapeutics and PharmaIN.
When was InSitu Biologics founded?
InSitu Biologics was founded in 2014.
Where is InSitu Biologics' headquarters located?
InSitu Biologics' headquarters is located in Oakdale, MN, US.
When was InSitu Biologics' last funding round?
InSitu Biologics' most recent funding round was for $5M (USD) in February 2021.
How much disclosed funding has InSitu Biologics raised?
As of Feb 24, 2021, InSitu Biologics has disclosed funding of $7M (USD). Undisclosed round amounts are excluded.
How many employees does InSitu Biologics have?
InSitu Biologics has 13 employees as of Feb 5, 2024.
Classification
- Ownership
- Technology
- Geographic Exposure
- Revenue
- Main Product
- Tags
- Also Known As
- InSitu Biologics, Inc
- Headquarters
- 3510 Hopkins Pl N
- Building 4
- Oakdale, MN, 55128
- US
- SEC CIK
- 0001723443
- EIN
- 82-3415514
- NAICS
- 540000Professional, Scientific, and Technical Services
- 541714Research and Development in Biotechnology (except Nanobiotechnology)
- 541000Professional, Scientific, and Technical Services
- 541700Scientific Research and Development Services
- 541710Research and Development in the Physical, Engineering, and Life Sciences
- SIC
- 2800Chemicals And Allied Products
- 2830Drugs
- 2834Pharmaceutical Preparations
- ISIC
- 2100Manufacture of pharmaceuticals, medicinal chemical and botanical products
- Industry
- —Biotechnology Companies
- —Health Care Companies
- —Medical Organizations
- —Pharmaceutical Companies
Show 14 more industry codes
- NAICS
- 320000Manufacturing
- 325400Pharmaceutical and Medicine Manufacturing
- 620000Health Care and Social Assistance
- 325000Chemical Manufacturing
- 623000Nursing and Residential Care Facilities
- 325410Pharmaceutical and Medicine Manufacturing
- 325412Pharmaceutical Preparation Manufacturing
- SIC
- 4000Railroad Transportation
- 8000Health Services
- 8700Engineering, Accounting, Research, Management, And Related Services
- 8040Offices And Clinics Of Other Health Practitioners
- 8730Research, Development, And Testing Services
- 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
- 8731Commercial Physical and Biological Research